KRAS and neoplasm: These in vitro results were confirmed in vivo using a murine model, which demonstrated that combined treatment with Nerofe and DOX resulted in reduced tumor size (Figure 4) along with the downregulation of KRAS expression in the tumor cells (Figure 5).